FDA Approves VENTANA PD-L1 Assay as a Companion Diagnostic for Atezolizumab

On October 22, 2021, Roche announced the U.S. Food and Drug Administration (FDA) approved its VENTANA PD-L1 (SP263) Assay as a companion diagnostic for patients with non-small cell lung cancer eligible for treatment with atezolizumab.

Read Roche's announcement for more information.

Posted 10/22/2021